| Kensington Center | |
| 225 Saint John Road, Elizabethtown, Kentucky 42701 | |
| (270) 769-3314 | |
| Name | Kensington Center |
|---|---|
| Location | 225 Saint John Road, Elizabethtown, Kentucky |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 82 |
| Occupancy Rate | 91.46% |
| Medicare ID (CCN) | 185443 |
| Legal Business Name | Hbr Elizabethtown, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1083030100 |
| Organization Name | GENESIS REHAB |
| Address | 225 Saint John Rd, Elizabethtown, KY 42701 |
| Phone Number | 270-769-3314 |
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
| NPI Number | 1235240383 |
| Organization Name | HBR ELIZABETHTOWN, LLC |
| Doing Business As | KENSINGTON CENTER |
| Address | 225 Saint John Rd, Elizabethtown, KY 42701 |
| Phone Number | 270-769-3314 |
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
| NPI Number | 1790492437 |
| Organization Name | KENSINGTON HEALTH CENTER LLC |
| Address | 225 St. John Road, Elizabethtown, KY 42701 |
| Phone Number | 270-769-3314 |
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
| NPI Number | 1801894118 |
| Organization Name | WELLS HEALTH SYSTEMS, INC. |
| Doing Business As | KENSINGTON MANOR |
| Address | 225 Saint John Rd, Elizabethtown, KY 42701 |
| Phone Number | 270-769-3314 |
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.23 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.5 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 18.03 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.99 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.67 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.91 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.92 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.93 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.64 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.9 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.16 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 51.87 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28.04 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.02 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.08 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 65.53 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 89.21 | 82.93 |
News Archive
forMD, an innovative provider of specialty physician communities, has launched a private online community for alumni of Hospital for Special Surgery (HSS), one of the nation's leading orthopedic hospitals.
Staying independent and in familiar surroundings as long as possible in old age - this is the wish of the most of us. It will be made possible by humanoid assistance robots that help people cope with everyday life and wearable robots that support the movements of the wearer.
The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery.
› Verified 2 days ago
Signature Healthcare Of Elizabethtown Location: 1117 Woodland Drive, Elizabethtown, Kentucky 42701 Phone: (270) 769-2363 | |
Helmwood Healthcare Center Location: 106 Diecks Drive, Elizabethtown, Kentucky 42701 Phone: (270) 737-2738 | |
Elizabethtown Nursing And Rehabilitation Center Location: 1101 Woodland Drive, Elizabethtown, Kentucky 42701 Phone: (270) 765-6106 | |
Baptist Health Hardin Location: 913 North Dixie Avenue, Elizabethtown, Kentucky 42701 Phone: (270) 706-1206 | |